

Table SI. Survival outcome of 44 patients exhibiting non-methylated PD-L1.

Characteristic	PFS			Patients, n	OS		
	mPFS (months)	χ ² -value	P-value		mOS, months	χ ² -value	P-value
Sex							
Male	5.3	0.369	0.544	24	10.2	0.003	0.956
Female	4.6			9	13.3		
Age, years							
≤60	4.6	0.002	0.964	15	10.2	0.614	0.433
>60	5.3			18	11.6		
Chemotherapy regimen							
Platinum/Fluorouracil	5.3	0.003	0.956	12	10.8	0.061	0.805
Paclitaxel/Fluorouracil	6.5			11	12.7		
Recurrence/Palliative surgery							
Recurrence	5.1	0.159	0.690	14	10.8	0.663	0.415
Palliative surgery	5.6			19	10.3		
Degree of differentiation							
Moderate or well	6.5	6.368	0.012	14	15.6	18.006	0.000 ^a
Poor	2.9			17	7.8		
Pathological type							
Simple adenocarcinoma	5.1	0.237	0.627	16	14	2.581	0.108
Other	5.0			16	8.8		
Tumor size							
>5 cm	6.4	0.008	0.929	16	10.0	2.131	0.144
≤5 cm	5.1			15	12.7		
Lymph node staging							
N0-N2	5.3	0.059	0.807	16	12.7	3.843	0.050
N3	5.6			14	9.6		

^aP<0.05. PD-L1, programmed cell death-Ligand 1; PFS, Progression-free survival; OS, Overall survival.